Temporary treatment during primary HIV infection does not affect virologic response to subsequent long-term treatment

PLoS ONE

Volumn 9, Issue 4, 2014, Pages

  Grijsen, Marlous L ^a,c   Wit, Ferdinand W N M ^b   Jurriaans, Suzanne ^a   Kroon, Frank P ^c   Schippers, Emile F ^d   Koopmans, Peter ^e   Gras, Luuk ^f   Lange, Joep M A ^b   Prins, Jan M ^a  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

^b AMSTERDAM INSTITUTE FOR GLOBAL HEALTH AND DEVELOPMENT   (Netherlands)

^c LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^d HAGA HOSPITAL   (Netherlands)

^e RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^f STICHTING HIV MONITORING   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; EFAVIRENZ; EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; LAMIVUDINE PLUS ZIDOVUDINE; LOPINAVIR PLUS RITONAVIR; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; VIRUS RNA;

ADULT; ANTIVIRAL ACTIVITY; ANTIVIRAL THERAPY; ARTICLE; CD4 LYMPHOCYTE COUNT; CONTROLLED STUDY; DATA ANALYSIS; DRUG EFFICACY; DRUG REEXPOSURE; DRUG RESPONSE; DRUG SUBSTITUTION; DRUG WITHDRAWAL; EARLY INTERVENTION; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; NONHUMAN; RANDOMIZED CONTROLLED TRIAL; REPEATED DRUG DOSE; TEMPORARY EARLY TREATMENT; VIRUS LOAD; VIRUS MUTATION; VIRUS RESISTANCE; VIRUS TRANSMISSION; ANTIVIRAL RESISTANCE; COMPARATIVE STUDY; DRUG ADMINISTRATION; DRUG EFFECTS; FOLLOW UP; GENETICS; HIV INFECTIONS; HUMAN IMMUNODEFICIENCY VIRUS 1; VIROLOGY;

ADULT; ANTI-HIV AGENTS; DRUG ADMINISTRATION SCHEDULE; DRUG RESISTANCE, VIRAL; FEMALE; FOLLOW-UP STUDIES; HIV INFECTIONS; HIV-1; HUMANS; LONG-TERM CARE; MALE; RNA, VIRAL; VIRAL LOAD;

EID: 84899066500     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0089639     Document Type: Article

References (11)

1. Grijsen ML, Steingrover R, Wit FW, Jurriaans S, Verbon A, et al. (2012) No Treatment versus 24 or 60 Weeks of Antiretroviral Treatment during Primary HIV Infection: The Randomized Primo-SHM Trial. PLoS Med 9(3):e1001196.
2. Hogan CM, Degruttola V, Sun X, Fiscus SA, Del RC, et al. (2012) The setpoint study (ACTG A5217): effect of immediate versus deferred antiretroviral therapy on virologic set point in recently HIV-1-infected individuals. J Infect Dis 205:87-96.
3. Fidler S, Porter K, Ewings F, Frater J, Ramjee G, et al. (2013) Short-Course Antiretroviral Therapy in Primary HIV Infection. N Engl J Med 368:207-217.
4. Fidler S, Oxenius A, Brady M, Clarke J, Cropley I, et al. (2002) Virological and immunological effects of short-course antiretroviral therapy in primary HIV infection. AIDS 16:2049-2054. (Pubitemid 35205269)
5. Taylor S, Boffito M, Khoo S, Smit E, Back D (2007) Stopping antiretroviral therapy. AIDS 21:1673-1682. (Pubitemid 47237553)
6. Lockman S, Shapiro RL, Smeaton LM, Wester C, Thior I, et al. (2007) Response to antiretroviral therapy after a single, peripartum dose of nevirapine. N Engl J Med 356:135-147. (Pubitemid 46089674)
7. Jourdain G, Ngo-Giang-Huong N, Le CS, Bowonwatanuwong C, Kantipong P, et al. (2004) Intrapartum exposure to nevirapine and subsequent maternal responses to nevirapine-based antiretroviral therapy. N Engl J Med 351:229-240. (Pubitemid 38922817)
8. El-Sadr WM, Lundgren JD, Neaton JD, Gordin F, Abrams D, et al. (2006) CD4+ count-guided interruption of antiretroviral treatment. N Engl J Med 355:2283-2296. (Pubitemid 44837777)
9. Fox Z, Phillips A, Cohen C, Neuhaus J, Baxter J, et al. (2008) Viral resuppression and detection of drug resistance following interruption of a suppressive non-nucleoside reverse transcriptase inhibitor-based regimen. AIDS 22:2279-2289.
10. Viread (tenofovir). (2006) Summary of procuct characteristics. Gilead Sciences International Limited. Cambridge, UK.
11. Taylor S, Jayasuriya A, Fisher M, Allan S, Wilkins E, et al. (2012) Lopinavir/ritonavir single agent therapy as a universal combination antiretroviral therapy stopping strategy: results from the STOP 1 and STOP 2 studies. J Antimicrob Chemother 67:675-680.